[Treatment of gastrointestinal neuroendocrine tumors with the somatostatin analog octreotide (Sandostatin)].
Somatostatin, a 14 amino acid peptide hormone, is a potent inhibitor for secretion of gastrointestinal hormones from endocrine cells. The clinical use of somatostatin for treatment of endocrine gastrointestinal tumours was limited due to its short half-life (2-3 min). Octreotide (Sandostatin), a long-acting somatostatin analogue, has been developed for subcutaneous use with an elimination half-life of about 45 min. This offers a new way of long-term treatment for patients with endocrine gastrointestinal tumours. The effect of octreotide in various forms of these diseases and its importance for the possible inhibition of tumour growth are described.
Stöckmann
F
F
Abt. Gastroenterologie und Endokrinologie, Medizinische Univ.-Klinik Göttingen.
Creutzfeldt
W
W
D001079:Apudoma / Q000188:drug therapy*; D002276:Carcinoid Tumor / Q000188:drug therapy; D003131:Combined Modality Therapy; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D003969:Vipoma / Q000188:drug therapy
D015282:Octreotide
Behandlung gastrointestinaler neuroendokriner Tumoren mit dem Somatostatin-Analog Octreotide (Sandostatin).